Annexon (ANNX) Liabilities and Shareholders Equity (2019 - 2026)
Annexon (ANNX) posted quarterly Liabilities and Shareholders Equity of $262.9 million for Q1 2026, down 13.25% year-over-year from $303.0 million in Q1 2025, and down 5.29% quarter-over-quarter from $277.6 million in Q4 2025.
Analysis
Annexon (ANNX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Annexon's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $262.9 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 13.25% year-over-year to $262.9 million; the TTM figure through Mar 2026 stood at $1.0 billion (down 28.08% YoY), while the FY2025 annual figure was $277.6 million, down 20.71% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $262.9 million, down from $277.6 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $406.1 million in Q2 2024, with the low at $203.8 million in Q3 2023.
- The 5-year median for Liabilities and Shareholders Equity is $277.6 million (2025), against an average of $285.2 million.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity jumped 85.84% in 2024, then sank 39.5% in 2025.
- Annexon's Liabilities and Shareholders Equity stood at $285.1 million in 2022, then grew by 4.41% to $297.7 million in 2023, then climbed by 17.6% to $350.1 million in 2024, then decreased by 20.71% to $277.6 million in 2025, then decreased by 5.29% to $262.9 million in 2026.
- Business Quant data shows ANNX's Liabilities and Shareholders Equity at $262.9 million in Q1 2026, $277.6 million in Q4 2025, and $229.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Annexon | 982.93 Mn | 982.93 Mn | - | 246.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 246.07 Mn |
| Mar 31, 2026 | 262.89 Mn |
| Dec 31, 2025 | 277.57 Mn |
| Sep 30, 2025 | 229.14 Mn |
| Jun 30, 2025 | 264.57 Mn |
| Mar 31, 2025 | 303.03 Mn |
| Dec 31, 2024 | 350.07 Mn |
| Sep 30, 2024 | 378.78 Mn |
| Jun 30, 2024 | 406.09 Mn |
| Mar 31, 2024 | 304.07 Mn |
| Dec 31, 2023 | 297.67 Mn |
| Sep 30, 2023 | 203.82 Mn |
| Jun 30, 2023 | 233.01 Mn |
| Mar 31, 2023 | 268.78 Mn |
| Dec 31, 2022 | 285.10 Mn |
| Sep 30, 2022 | 312.72 Mn |
| Jun 30, 2022 | 220.70 Mn |
| Mar 31, 2022 | 250.57 Mn |
| Dec 31, 2021 | 287.04 Mn |
| Sep 30, 2021 | 310.16 Mn |